Ostocal-D

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ostocal-D

Quick Facts

Property Description
Active ingredient Calcium Carbonate, Dihydrotachysterol
Form Oral solid dosage form (tablet or capsule)
Pharmacological class Mineral Supplement, Vitamin D Analog
Common use Supporting calcium homeostasis and bone mineralization
Origin Combination of a mineral compound and a synthetic derivative

What Type of Medicine is Ostocal-D and How is it Classified?

Ostocal-D is classified as a combination product that functions as both a Mineral Supplement and a potent Vitamin D Analog, typically presented as an oral solid dosage form. This preparation is designed to be taken orally to address the body's need for essential minerals and their efficient utilization. Dihydrotachysterol is categorized as a Bone Density Conservation Agent due to its recognized role in regulating bone mineralization. This classification indicates the medicine's primary role is to maintain the structural integrity of the skeleton, often in patient groups needing reliable mineral support.


What is the Composition of Ostocal-D?

The active composition of Ostocal-D includes two distinct ingredients: Calcium Carbonate and Dihydrotachysterol. Calcium Carbonate is a mineral compound that serves as a high-concentration source of elemental calcium. The second component, Dihydrotachysterol, is a synthetic Vitamin D analog utilized in clinical settings to manage conditions associated with certain metabolic disorders. Unlike standard Vitamin D, the Dihydrotachysterol in Ostocal-D is distinguished by its different metabolic pathway, which is clinically recognized for providing predictable control over serum calcium levels.


What is the General Purpose of Ostocal-D?

The general purpose of Ostocal-D is to support and maintain the body's mineral balance, with a focus on normalizing the concentration of calcium in the blood and tissues. The agent is used to support the body in overcoming states of hypocalcemia (low serum calcium levels). By providing the essential mineral and an active regulator, the medicine aims to enhance the body's intestinal calcium absorption and promote its retention, thereby supporting the fundamental process of bone mineralization and overall skeletal integrity.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Ostocal-D?

Possible Side Effects and Safety Information

The following safety information for products containing Calcium Carbonate and Cholecalciferol (Vitamin D3), such as Ostocal-D, is based on authoritative government regulatory documents.

Adverse Reactions and Systemic Concerns

The most commonly documented adverse reactions relate to the Gastrointestinal System and include constipation, upset stomach, nausea, vomiting, loss of appetite, and stomach pain. These are typically mild and expected.

More serious adverse reactions are primarily linked to overdose or excessively high intake, leading to Hypercalcemia (too much calcium in the blood) and Hypervitaminosis D. Symptoms of serious toxicity may include increased thirst or urination, confusion, mental changes, unusual weakness, and irregular heartbeats. Serious long-term effects include the risk of Nephrolithiasis (kidney stones) and Milk-Alkali Syndrome.

Safety Restrictions and Limitations

Contraindications include a known allergy to the product's components, as well as pre-existing conditions involving high levels of calcium (Hypercalcemia) or Vitamin D (Hypervitaminosis D).

Drug Interactions are a critical safety consideration: the medicine should not be taken near the time of certain antibiotics (e.g., tetracyclines, fluoroquinolones) or thyroid medications, as calcium can prevent their proper absorption. The product is also restricted for use as an antacid to typically no more than two weeks unless monitored by a health professional.

Population-Specific Notes: Caution is advised for individuals with kidney disease, sarcoidosis, or heart conditions. Excessive Vitamin D intake during pregnancy requires medical supervision.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Ostocal-D is officially characterized by the development of Hypercalcemia, resulting from excessive exposure to the Vitamin D analog component. Regulatory documents detail a progression of symptoms, often starting with non-specific signs such as anorexia, nausea, and vomiting, alongside increased thirst (polydipsia) and frequent urination (polyuria). Other documented manifestations include headache, fatigue, somnolence, and a metallic taste.

The toxicity can escalate to severe manifestations affecting major systems, including neurological effects like confusion, stupor, and coma, as well as cardiovascular effects like cardiac arrhythmias. Long-term or severe exposure carries the risk of serious complications, notably renal failure and nephrocalcinosis. Immobilized patients and newborns are cited in official labeling as populations with particular vulnerability to the severe effects of this toxicity.

Overdosage is considered sufficiently severe to require immediate emergency attention. The mandated immediate step is the withdrawal of the vitamin component. Regulatory guidance specifies that a severe state, known as a hypercalcemic crisis, requires urgent medical care. Treatment is defined as symptomatic and supportive, involving procedures such as aggressive hydration with intravenous saline and the use of loop diuretics; no specific antidote is officially documented.

Therapeutic Uses of Ostocal-D

What Ostocal-D Treats: Main Uses and Benefits

The primary therapeutic focus of this medication is to provide supportive relief that helps ease the overall symptom burden related to systemic or localized discomfort. This combination is commonly used to help manage conditions such as Hypoparathyroidism, Renal Osteodystrophy, Rickets, Osteomalacia, and Osteoporosis, and is relevant in situations with significant discomfort related to Hypocalcemia.

This combination therapy is commonly used to help with symptoms related to systemic imbalance and is relevant in contexts involving heightened systemic burden. The medication offers supportive relief by managing the neuromuscular hyperexcitability and is relevant for easing distressing manifestations like involuntary muscle spasms and tetany.

It is further applied across conditions presenting with systemic or localized discomfort where the skeletal structure is affected. The core benefit is to support skeletal integrity, which generally helps maintain a sense of stability when structural health is affected.

Quick Fact: Relevant for Easing Acute Symptoms
Symptom Cluster Symptoms of increased neurological or muscular activity (spasms and Tetany)
Therapeutic Benefit Assists with addressing symptoms associated with acute or disruptive episodes
Contextual Use Relevant in situations where symptoms may intensify temporarily

Eligibility and Restrictions for Use

Who Cannot Use Ostocal-D

The eligibility profile for Ostocal-D (Calcium Carbonate and Dihydrotachysterol) is strictly defined by official regulatory documents based on the potent effects of its Vitamin D analog component. The medicine is formally contraindicated and must not be used by individuals with pre-existing Hypercalcaemia (high calcium levels in the blood) or Hypervitaminosis D (Vitamin D toxicity), as the drug is designed to increase calcium absorption. It is also prohibited for breastfeeding mothers due to the risk of transmitting the active metabolite to the infant. Patients with Hypersensitivity to the active ingredients or any excipient must also avoid use.


Restricted and Conditional Use

Use is restricted in populations with conditions like severe renal impairment and Hyperphosphatemia, where intensive monitoring and concurrent management (such as phosphate binders) are mandated to prevent tissue calcification. Use during pregnancy is strictly conditional, permitted only when the potential benefit is determined to outweigh the documented risks to the fetus.


Eligible Populations

The medicine is primarily intended for adult and pediatric populations with conditions causing low blood calcium, such as Hypoparathyroidism and Renal Osteodystrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe several clinically significant interaction patterns for the combination of Calcium Carbonate and Dihydrotachysterol.

Contraindicated and High-Risk Combinations

Co-administration with other Vitamin D analogs is generally restricted due to the potential for additive effects that increase the risk of hypercalcemia. A clinically significant pharmacodynamic interaction exists with Thiazide Diuretics, which may reduce calcium excretion, thus potentiating the risk of hypercalcemia. This elevated calcium concentration may also increase the sensitivity to Cardiac Glycosides (like Digoxin), which can exacerbate the risk of cardiac arrhythmias.

Absorption and Timing Requirements

Many medicines require mandated administration separation from Ostocal-D. Tetracycline and Quinolone Antibiotics, Bisphosphonates, and thyroid hormone preparations like Levothyroxine must be spaced out, typically by several hours, to prevent the calcium component from binding with and reducing the absorption of the co-administered drug. The absorption of the Calcium Carbonate component can be reduced by acid-suppressive agents (Proton Pump Inhibitors/H2 Blockers), and the absorption of Dihydrotachysterol is reduced by agents such as Cholestyramine.

Food and Population-Specific Interactions

Official information notes that Grapefruit Juice may alter plasma levels of the Vitamin D analog. Additionally, foods high in oxalic or phytic acid can impair calcium absorption. Patients with Impaired Renal Function face an increased susceptibility to toxic effects, including ectopic calcification, when combining Ostocal-D with certain other products.

Mechanism of Action

Ostocal-D's action is governed by two complementary components: the Vitamin D precursor and the calcium source.

VDR Agonism and Gene Transcription

The Vitamin D3 component (Cholecalciferol) is activated by the liver and kidneys into Calcitriol, which binds to the Vitamin D Receptor (VDR). This VDR agonism modulates gene transcription, initiating the cellular machinery needed to produce proteins (like Calbindin) that are essential for handling calcium. The mechanism directly influences the mineral homeostasis pathway by setting the conditions for efficient mineral absorption and control.

Intestinal Absorption and Systemic Substrate Supply

The Calcium Carbonate provides the necessary elemental calcium ( Ca^2+) substrate, which is released in the stomach for uptake in the small intestine. The mechanism works synergistically, where the VDR agonism enhances the capacity of the gut cells to actively transport this supplied calcium into the circulation. This action results in the core physiological change of elevating serum calcium concentration, a physiological precursor for neuromuscular excitability and bone matrix deposition.

Regulation of the Parathyroid Hormone (PTH) Axis

The resulting increase in circulating Calcitriol and calcium levels exerts a negative feedback signal on the parathyroid glands. This systemic regulatory step modulates the activity of the mineral control system, contributing to regulated bone turnover and stable plasma calcium levels. This action modulates the activity of the mineral homeostasis pathway, which contributes to the stability of these ion concentrations in the bloodstream.

Dosage and Administration Information

The usage of Ostocal-D, a preparation combining Calcium Carbonate and the Vitamin D analog Dihydrotachysterol, is defined by a strict, titration-based protocol outlined in established protocols. The administration process centers on achieving and maintaining a specific serum calcium level through highly individualized oral dosing.


Administration Scope

Aspect Instruction / Rule
Route of administration: Oral administration only. The medicine is available in oral solution or solid forms such as capsules or tablets.
Dosing schedule: Initial Adult Dose: Typically ranges from 0.8 mg to 2.4 mg of Dihydrotachysterol once daily for several days. Maintenance Adult Dose: Ranges from 0.2 mg to 1.0 mg once daily, with an average of 0.6 mg.
Preparation requirements (if applicable): The treatment must be used concomitantly with an adequate daily intake of elemental calcium for proper effect.
Age-group administration rules: Dosing guidelines are specified for various age groups. Neonatal Doses typically begin with 0.05 mg to 0.1 mg once daily. Infant and Child Maintenance Doses range from 0.5 mg to 1.5 mg once daily.

Instruction Classifications (High-Level)

Classification Principle
Administration method type: Oral
Frequency pattern: Once daily
Basis of application: Clinical guidelines
Use-context constraints: Requires concomitant calcium supplementation and laboratory monitoring to direct dosing.

Resulting Procedural Structure

Procedural step sequence (Titration and Maintenance):

  • Administer the medicine orally, once daily, ensuring concurrent adequate daily calcium intake.
  • Initiate treatment with the defined starting dose for a short period, and commence frequent serum calcium monitoring.
  • Adjust the dose to the maintenance range based on blood test results.
  • Titrate the dose at intervals of 4 to 8 weeks to maintain serum calcium within the target range of 9 to 10 mg/dL.

Connection to the overall use protocol: The use protocol is a structured, long-term regimen that defines daily oral dosing and is strictly procedural. It mandates frequent, laboratory-based monitoring of serum calcium levels to guide dose adjustments, ensuring the usage aligns precisely with the standard parameters established for management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ostocal-D

Ostocal-D combines Calcium Carbonate and Dihydrotachysterol. The clinical evaluation of these active components has been examined in the context of mineral balance and bone health. The evidence landscape includes various study types, from Randomized Controlled Trials (RCTs) to long-term observational cohorts, with findings that describe patterns observed in the studies regarding patient experiences and how symptoms evolved in the observed populations.


Evidence for Use in Hypoparathyroidism and Acute Mineral Imbalance

Research has explored the use of the medicine’s components in clinical situations involving Hypoparathyroidism and related states where acute hypocalcemia (low calcium levels in the blood) may occur. Studies monitored outcomes such as the measurement of serum calcium and serum phosphorus concentrations, and the tracking of the calcium-phosphate product. Studies reported that management protocols were associated with the measurement of mineral levels within a defined range, with observational data tracking these patterns over multiple years.


Evidence for Use in Bone Development and Mineralization Disorders

The active components were also evaluated in conditions affecting bone structure and development, such as Rickets and Osteomalacia. Researchers monitored the achievement of serum calcium maintenance, utilized X-rays to measure radiographic healing, and assessed bone mineralization. While findings describe patterns observed in the studies related to the measurement of mineral changes, a significant portion of the core evidence in this area is historic.


What Research Gaps and Uncertainties Remain

While research has explored patterns related to the medicine’s components, the available evidence also highlights areas where certainty remains low or where more research is needed. The research base is often built upon comparative trials, meaning that comparative evidence is lacking for the specific two-component formulation against a placebo. Additionally, dedicated, multi-year fracture risk reduction trials focusing on this combination are not a primary focus of the research.

Key Studies & References Calcium Carbonate: Description and Function as a Source of Elemental Calcium - NIH StatPearls

Frequently Asked Questions (FAQ)

Common questions about Ostocal-D (FAQ)


Q: Is Ostocal-D the same as other vitamin D supplements I see at the store?

Official documents describe the Vitamin D component of Ostocal-D, Dihydrotachysterol, as a synthetic analog. It is distinguished from standard Vitamin D by its unique metabolic pathway. For example, it is activated in the liver and does not require the final processing step in the kidney, which may be impaired in some patients.

Q: Why did my doctor prescribe Ostocal-D and not a different supplement?

Regulatory data indicates that the Dihydrotachysterol component is specifically intended for managing certain regulated conditions, such as Hypoparathyroidism and Renal Osteodystrophy. Its unique characteristics and mechanism align it for use in these patient populations, as defined by official indications.

Q: How quickly should I expect to see any effects from Ostocal-D?

Regulatory documents indicate that the onset of action for Dihydrotachysterol is typically rapid, often measurable within approximately two hours. Individual physiological responses may affect the exact time frame.

Q: How long does Ostocal-D stay in my system?

Regulatory documentation states that Dihydrotachysterol has a relatively short half-life (measured in hours). This short duration of effect is one characteristic of the medicine, which allows for potentially quicker dose adjustments when monitored by a healthcare professional.

Q: Is it normal to feel slightly nauseous when first taking Ostocal-D?

Official safety documents list nausea and vomiting as documented adverse events, which are important to monitor. These symptoms are linked to hypercalcemia (too much calcium), and the treatment protocol includes regular blood monitoring.

Q: Does Ostocal-D interact with blood pressure medication?

Official documents specify interactions with certain cardiovascular medications. These include Thiazide Diuretics (a type of water pill) and some Calcium Channel Blockers, due to potential risks related to increased calcium levels.

Q: Does alcohol change the way Ostocal-D works?

Regulatory safety documents typically contain specific information regarding the use of the medicine with alcohol. Official warnings or precautions are usually detailed regarding potential associated risks.

Q: Is there a pediatric formulation of Ostocal-D?

Regulatory dosing instructions include specific guidelines for Neonatal, Infant, and Child populations. This strongly indicates that the regulatory authority has approved a specific, appropriate formulation (such as an oral solution or low-dose capsule) for use in children.

Q: Why do some sources say Ostocal-D should be taken with food?

The Calcium Carbonate component, which provides elemental calcium, is often instructed to be taken with food. Taking it with food may help to improve its absorption in the body and can minimize the chance of common stomach upset associated with calcium supplements.

Q: What happens if I miss a scheduled amount of Ostocal-D?

Regulatory documents typically include standard guidance describing the appropriate procedural steps to follow in the event a scheduled administration is missed. This standard guidance is typically found within the official patient information provided with the product.

Q: Are there any reported interactions between Ostocal-D and common over-the-counter painkillers?

Official interaction summaries do not typically list a direct interaction with common over-the-counter painkillers like Ibuprofen or Acetaminophen. However, potential for absorption-based interactions involving the calcium component exists, making it standard practice for health professionals to review a patient's full medication list.

Q: Is there any public research on Ostocal-D's use in younger populations?

Studies have examined the use of Ostocal-D's active components in conditions that affect children, such as Rickets and specific forms of Hypophosphatemia. This body of research helps inform the pediatric dosing guidelines found in official regulatory documents.

Q: Does Ostocal-D contain any allergens like gluten or lactose?

The official composition and excipient list, found in the full regulatory documentation, details the presence of all inactive ingredients. This list contains details on inactive ingredients, which may include substances such as lactose or other commonly recognized allergens.

Q: Does taking Ostocal-D affect my energy levels?

Official safety information lists unusual weakness and fatigue as symptoms that may be associated with early signs of drug toxicity. These signs are linked to the risk of high blood calcium levels.

Q: Can Ostocal-D cause headaches?

Yes, official safety information lists headache as one of the symptoms that can be associated with early signs of drug toxicity. These symptoms are typically associated with the risk of high blood calcium levels, which are routinely monitored as part of the treatment protocol.

Q: How is Ostocal-D eliminated from the body?

Regulatory documents factually describe that the metabolites of the Vitamin D component are primarily excreted through the bile and feces. This is part of the drug's known pharmacokinetics.

Q: Can I buy Ostocal-D without a prescription?

Regulatory documentation for the active component, Dihydrotachysterol, classifies the drug as prescription only in certain jurisdictions. The drug is classified as a prescription-only medicine.

Q: Are there any common signs that Ostocal-D might not be suitable for me?

Official safety information advises caution if a patient has pre-existing high calcium levels (hypercalcemia). Additionally, documented signs of toxicity, such as increased thirst, headache, or unusual weakness, are often monitored.

Q: Is Ostocal-D a widely used and recognized product in medical practice?

Official documents classify Ostocal-D's component, Dihydrotachysterol, as a Bone Density Conservation Agent and a Vitamin D Analog. This formal classification and listing of specific clinical indications demonstrate regulatory recognition of its therapeutic role.

Q: What is the distinction between a drug and a supplement in the context of Ostocal-D?

Regulatory sources classify Ostocal-D as a prescription-only medicine belonging to the vitamin drug class, intended to treat specific, regulated conditions like Hypoparathyroidism and Renal Osteodystrophy. Its status as a prescription-only medicine intended to treat specific, regulated conditions formally distinguishes it from an over-the-counter dietary supplement.

Q: Does sun exposure change how effective Ostocal-D is?

The mechanism of Dihydrotachysterol is designed to function independently of the typical steps of Vitamin D activation. Since natural Vitamin D activation is often linked to sunlight exposure, Dihydrotachysterol is used precisely when that natural pathway is impaired.

Q: Does Ostocal-D interact with supplements like iron or zinc?

Official interaction data does not typically list a direct interaction with common mineral supplements like Iron or Zinc that requires special dosage spacing. However, due to the calcium component, there is a general potential for absorption issues that health professionals typically consider.

How should Ostocal-D be stored and disposed of?

How to Store and Dispose of Ostocal-D?

This medicine must be stored under specific environmental conditions to maintain its stability and effectiveness, as defined by regulatory standards. The product is required to be stored in a cool and dry place, with the temperature maintained below 30 C or at Controlled Room Temperature. It must be protected from light and kept in its original, tightly closed container; it is also instructed not to freeze the medication.

Child Safety and Disposal

It is a mandatory safety requirement to keep Ostocal-D out of the sight and reach of children.

Unused or expired medicine must be properly discarded. Regulators advise utilizing a drug take-back program if available. If not, the product must be mixed with an undesirable substance (e.g., dirt) and sealed before being placed in household trash; the medicine should not be disposed of in the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ostocal-D found in:

A-Z Index: